Translate this page into:
Acute-onset muscle weakness in acute leukemia: A common but often missed cause
*Corresponding author: Kaustav Ghosh, Department of Hematology, Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India. ghoshrony94@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Ghosh K. Acute-onset muscle weakness in acute leukemia: A common but often missed cause. J Hematol Allied Sci. 2023;3:166-7. doi: 10.25259/JHAS_38_2023
An 18-year-old female newly diagnosed with precursor T-cell acute lymphoblastic leukemia presented with progressive pallor requiring recurrent blood transfusions; examination revealed generalized lymphadenopathy and mild splenomegaly. The complete blood count on admission was hemoglobin 7.6 g/dL, total leukocyte count 134,500/cumm (Neutrophils-25%, Lymphocytes-30%, and blasts-45%), and platelet count of 16,000/cumm. The patient was started on the BFM 2002 induction protocol along with prophylaxis for tumor lysis syndrome. On day 3 of therapy, the patient complained of severe bilateral muscle pain and weakness. Examination revealed bilateral lower-limb flaccid paralysis. A serum sample was sent for electrolyte analysis, and an urgent electrocardiogram (ECG) was done. ECG revealed a wide QRS complex with a loss of P waves and a typical “sine wave” pattern [Figure 1]. The patient was immediately started on injection of calcium gluconate, IV glucose insulin drip, salbutamol nebulization, and potassium binding (calcium polystyrene sulfonate) sachet. Later on, biochemistry reports revealed serum potassium 7.6 meq/L, serum calcium 9.6 meq/L, and serum magnesium 2.1 meq/L. Hyperkalemia is a medical emergency that can lead to sudden cardiac arrest; hence, non-specific signs and symptoms such as muscle pain or weakness associated with/without vomiting, palpitations, or chest pain should alert the physician to take appropriate measures.[1]
Ethical approval
The Institutional Review Board approval is not required.
Declaration of patient consent
Patient’s consent not required as patient’s identity is not disclosed or compromised.
Conflicts of interest
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation
The author confirms that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Financial support and sponsorship
Nil.
References
- Tumor lysis syndrome In: StatPearls. Treasure Island, FL: StatPearls Publishing; Available from: https://www.ncbi.nlm.nih.gov/books/NBK518985/ [Last accessed on 2022 Oct 31]
- [Google Scholar]